Alzheimer’s Disease (AD) Pipeline Insight Report 2020: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alzheimer’s Disease (AD) – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Alzheimer’s Disease (AD) – Pipeline Insight, 2020,” report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Treatment

Treatment for Alzheimer’s Disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications – cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.

Alzheimer’s Disease (AD) Emerging Drugs Chapters

This segment of the Alzheimer’s Disease (AD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alzheimer’s Disease (AD) Emerging Drugs

(Read more…)

BAN2401: Eisai

BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.

Gantenerumab: Hoffmann-La Roche

Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.

Alzheimer’s Disease (AD): Therapeutic Assessment

This segment of the report provides insights about the different Alzheimer’s Disease (AD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alzheimer’s Disease (AD)

There are approx. 100+ key companies which are developing the therapies for Alzheimer’s Disease (AD). The companies which have their Alzheimer’s Disease (AD) drug candidates in the most advanced stage, i.e. phase III include, Eisai.

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Alzheimer’s Disease (AD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alzheimer’s Disease (AD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alzheimer’s Disease (AD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alzheimer’s Disease (AD) drugs.

Key Players

• Eisai
• Biogen
• Changchun Huayang High-tech Co. Ltd.
• Hoffmann-La Roche
• vTv Therapeutics
• AZTherapies
• Cerecin
• Neurotrope
• Lyndra
• AC Immune
• INmune Bio
• Cassava Sciences
• EIP Pharma
• Neuraly
• AB Science
• Cortexyme
• Anavex Life Sciences
• Athira Pharma
• Time Therapeutics
• Prilenia Therapeutics
• Denali Therapeutics Inc.

Key Products

• BAN2401
• Elenbecestat (E2609)
• Octohydroaminoacridine Succinate
• Gantenerumab
• Azeliragon (TTP488)
• ALZT-OP1
• AZT-211
• Tricaprilin
• Bryostatin-1
• Donepezil/memantine extended release
• ACI-3024
• INB03
• Sumifilam
• Neflamapimod
• Pegylated exenatide
• Masitinib
• Atuzaginstat
• Blarcamesine
• NDX-1017
• Bromocriptine
• Pridopidine
• DNL788

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/351ba7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900